$MXCT

MAXCYTE, INC. (MXCT): Submission of Matters to a Vote of Security Holders

MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. MaxCyte, Inc._June 17, 2026 0001287098 false 0001287098 2026-06-17 2026-06-17 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ FORM 8-K ​ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of e

Original reporting
Published Jun 17, 2026, 8:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$MXCT
Neutral
high confidence
Mentioned
$MXCT
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MXCTNeutralLow
01

Why it matters

The disclosure confirms shareholder approval of directors and the independent registered public accounting firm for fiscal year ending December 31, 2026, but does not change fundamentals.

02

Market read

Primarily administrative governance information; not a catalyst for earnings, guidance, or major corporate events.

03

What to watch

If there were contested director elections or auditor disputes, vote counts could matter; here, the filing provides no indication of controversy or outcomes beyond standard approval.

Relevance 6/10Novelty 2/10Timing: Filed June 17, 2026 (after market hours)

Background

Form 8-K Item 5.07 is used to report matters submitted to a vote of security holders following an annual meeting.

Company-level read

Ticker impact

$MXCTNeutralHigh confidence
Context

MaxCyte’s 8-K reports stockholder voting results: election of Class II directors and ratification of CohnReznick as FY2026 auditor.

Expected impact

Low likelihood of sustained price impact; any reaction is likely limited to short-term sentiment around governance items.

Evidence & confidence

The filing only tallies votes at the June 17, 2026 annual meeting and does not introduce new strategy, financial results, or material transactions.

Market effects

No meaningful read-across to the biotech/bioprocessing tools sector from this governance-only vote tally.

None.

None.

Counterpoint

Traders could treat auditor ratification as a minor positive for governance continuity, but the disclosure lacks any change in audit scope or financial reporting risk.

Key entities

  • MaxCyte, Inc.

    Subject of the 8-K; reports annual meeting voting results for director election and auditor ratification.

  • CohnReznick LLP

    Ratified as MaxCyte’s independent registered public accounting firm for FY ending Dec. 31, 2026.

Related articles

$MXCTMed

MAXCYTE, INC. (MXCT): Results of Operations and Financial Condition

MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mxct-20260812xex99d1.htm EX-99.1 Exhibit 99.1 ​ MaxCyte Reports Second Quarter 2026 Financial Results · Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue · Reitera

Med

AI nuclear power firm Fermi finally has a new CEO

Fermi, an AI nuclear power company, named Lee McIntire as CEO more than three months after firing co-founder Toby Neugebauer. Fermi said McIntire previously led CH2M Hill and TerraPower. The firm is developing Project Matador in Amarillo, Texas, and said it signed TensorWave as its first binding customer lease. Fermi stock rose nearly 23% since Monday.

$NVDAMed

Nvidia's AI revolution will be securitized

Nvidia said it plans to raise about $500 billion to finance AI infrastructure buildouts with six North American investment firms: Apollo, BlackRock, Blackstone, Brookfield, Goldman Sachs, and KKR. The firms may use GPU securitizations to spread exposure across investors. Nvidia may provide residual-value support of up to 25%, according to the company.

$FAMed

First Advantage shares fall 8% after Silver Lake secondary share offering

First Advantage (NASDAQ:FA) shares fell about 8% after Silver Lake-affiliated funds announced a secondary offering of 12.5 million FA shares. Bloomberg reported a marketing range of $22.20 to $23.59 versus Monday’s $23.59 close. The company will not sell shares or receive proceeds. J.P. Morgan is underwriter; a 30-day lock-up applies to the seller, with some shares to limited partners.

$AREMed

Alexandria Real Estate Sets 7.25% Interest Through Feb. 15, 2032

Alexandria Real Estate Equities (NYSE: ARE) priced a $1.0 billion public offering of 7.250% Series A fixed-to-fixed reset rate junior subordinated notes due 2057 at 100% of principal. Interest is 7.250% until Feb. 15, 2032, then resets to the 5-year U.S. Treasury plus 2.889%, with a 7.250% floor. Closing expected around Aug. 21, 2026; proceeds for general corporate purposes.